This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT03600480 |
|---|---|
| Status | Completed |
| Phase | Phase 1 |
| Sponsor | Novo Nordisk A/S |
| Enrollment | 96 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Obesity; Overweight |
| Interventions | NNC0174-0833; Semaglutide; Placebo (NNC0174-0833) |
| Start | Jul 25, 2018 |
| Primary completion | Jun 12, 2020 |
| Study completion | Jun 12, 2020 |
| Results posted | Not yet |
| Registry last updated | Nov 17, 2021 |
Compounds on this site that cite this trial
What the registry says the trial is about
The aim of this study is to find out how NNC0174-0833 taken with semaglutide works in people who are overweight or obese. Both study medicines have been investigated on their own. The study also looks at how the study medicines behave in participant's body and how they are removed from the participant's body. Participants will get 1 of the following 2 treatments - which treatment any participant gets is decided by chance: Semaglutide (a new medicine) and NNC0174-0833 (a potential new medicine), or semaglutide and placebo (a "dummy medicine similar to the study medicine but without active ingredients). Participants will get 2 injections per week for 20 weeks. A study nurse at the clinic will inject the medicine with a needle in a skin fold in the participant's stomach area. The study will last for about 16 months, but duration of participation for any participant will last up to about 7.5 months. Participants will have 28 clinic visits with the study staff and some will be overnight visits. Participants will be asked about their health, medical history and habits including mental health questionnaires.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Number of treatment emergent adverse events (TEAEs) | From first administration of NNC0174-0833 (Day 1) to completion of the post-treatment follow-up (Day 176) |
4 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
